海外の治験の状況「前立腺癌」での検索結果
107件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not Recruiting
- Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients - Leuprolide 3.75 mg
- prostate cancer br>MedDRA version: 6.0 Level: LLT Classification code 10007113
- Austria, Czech Republic, Germany, Hungary, Italy, Spain, United Kingdom
- 2005-10-21
Not Recruiting
- A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Russian Federation, Singapore, Slovakia, Spain, Sweden, United Kingdom, United States
- 2013-10-29
Not Recruiting
- A study of patients with prostate cancer who have previously been treated with docetaxel-based chemotherapy, where patients receive either study drug or placebo
- Patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy MedDRA version: 14.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belgium, Canada, Chile, France, Germany, Italy, Netherlands, Poland, South Africa, Spain, United Kingdom, United States
- 2009-09-03
Not recruiting
- The effects of cranberry capsules on cystitis in men treated with radiation for prostate cancer
- Acute non-infectious radiation cystitis;Prostate Cancer
- ,Outside, New Zealand
- 2011-08-19
Not Recruiting
- A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who are responsive to such therapy - ICELAND Study
- Histologically or cytologically confirmed adenocarcinoma of the prostate (PCa) meeting the following criteria: - Locally adv. (stage T3 or T4) PCa, N0 or N+, M0 with PSA >= 5 ng/ml, or - Relapsing PCa following radical prostatectomy for clinically localized PCa with a serum PSA of >= 0.4 ng/ml or, - Relapsing PCa following radiotherapy with a serum PSA of >= 1 ng/ml as compared to a previous reference value. MedDRA version: 8.0 Level: LLT Classification code 10060862
- Austria, Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Ireland, Italy, Portugal, Spain, Sweden, United Kingdom
- 2005-12-05
Not recruiting
- Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate
- Prostate Cancer
- Austria, Belgium, Denmark, France, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
- 2004-06-10
Not Recruiting
- A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Mexico, Netherlands, Peru, Poland, Puerto Rico, Romania, Russian Federation, Spain, United Kingdom, United States
- 2015-11-12
Not Recruiting
- A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, India, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Serbia, Singapore, South Africa, Sweden, Switzerland, Taiwan, Province of China, United Kingdom, United States
- 2015-11-11
Not recruiting
- A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
- Prostate Cancer
- Argentina, Australia, Austria, Belgium, Brazil, Chile, China, Czechia, France, Germany, Hong Kong, Israel, Italy, Mexico, New Zealand, Poland, Romania, Russian Federation, Singapore, Spain, Turkey, United Kingdom, United States
- 2019-09-20
Not Recruiting
- Improvement of detection of clinically significant prostate cancer by combination of molecular urine markers and multiparametric MRI of the prostate
- ;C61 - Malignant neoplasm of prostate
- Austria, Germany
- 2019-12-30